Biohaven (NYSE:BHVN) Issues Quarterly Earnings Results

Biohaven (NYSE:BHVN) posted its quarterly earnings results on Monday. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32, FiscalAI reports.

Biohaven Price Performance

Shares of BHVN traded up $0.26 during mid-day trading on Monday, hitting $11.78. 1,620,630 shares of the stock were exchanged, compared to its average volume of 2,646,636. The company has a debt-to-equity ratio of 1.91, a quick ratio of 2.86 and a current ratio of 2.86. The company has a market cap of $1.25 billion, a PE ratio of -1.55 and a beta of 1.14. Biohaven has a 52-week low of $7.48 and a 52-week high of $36.95. The firm has a 50-day moving average of $11.57 and a two-hundred day moving average of $12.75.

Analysts Set New Price Targets

Several research analysts recently weighed in on BHVN shares. BTIG Research reaffirmed a “buy” rating and issued a $16.00 target price on shares of Biohaven in a report on Tuesday, November 18th. UBS Group downgraded Biohaven from a “buy” rating to a “neutral” rating and decreased their target price for the company from $26.00 to $11.00 in a research note on Wednesday, November 26th. Bank of America downgraded Biohaven from a “buy” rating to a “neutral” rating and set a $10.00 price target for the company. in a research note on Wednesday, November 5th. The Goldman Sachs Group upgraded shares of Biohaven to a “strong-buy” rating in a research report on Friday, February 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Biohaven in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Biohaven presently has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Hedge Funds Weigh In On Biohaven

Several institutional investors have recently bought and sold shares of BHVN. PNC Financial Services Group Inc. raised its holdings in shares of Biohaven by 113.7% in the third quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after buying an additional 1,268 shares during the period. Arax Advisory Partners grew its position in Biohaven by 943.3% in the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after acquiring an additional 4,443 shares during the last quarter. Focus Partners Wealth purchased a new stake in Biohaven in the third quarter worth $87,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of Biohaven by 145.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 9,152 shares of the company’s stock worth $103,000 after purchasing an additional 5,417 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Biohaven by 198.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,031 shares of the company’s stock valued at $113,000 after purchasing an additional 5,341 shares during the period. Institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.